{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:38Z","timestamp":1792784918365,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institutes of Allergy and Infectious Diseases","award":["AI158060, AI150091, AI143348, AI147499, AI143326, AI138764, AI124911, and AI110902"],"award-info":[{"award-number":["AI158060, AI150091, AI143348, AI147499, AI143326, AI138764, AI124911, and AI110902"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The first-generation Spike-based COVID-19 vaccines reduced the risk of hospitalization, serious illness, and death from SARS-CoV-2 infections. However, waning immunity failed to prevent immune escape, resulting in multiple variants of concern (VOCs) and prolonging the pandemic. We hypothesize that next-generation CoV vaccines incorporating highly conserved SARS-CoV-2 T cell antigens would confer potent, broad, long-lasting cross-protective immunity against multiple VOCs. In this study, we identified 10 non-Spike antigens common and highly conserved across 8.7 million SARS-CoV-2 strains, prior VOCs, SARS-CoV-1, MERS-CoV, seasonal human cold CoVs, and animal CoVs. Seven antigens were preferentially recognized by CD8\n                    <jats:sup>+<\/jats:sup>\n                    and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells from unvaccinated asymptomatic COVID-19 patients, irrespective of VOC. Three conserved antigens (NSP2, NSP14, Nucleoprotein) administered to golden Syrian hamsters: (\n                    <jats:italic>i<\/jats:italic>\n                    ) induced high frequencies of lung-resident polyfunctional CXCR5\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    T\n                    <jats:sub>FH<\/jats:sub>\n                    cells, GzmB\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    \/CD8\n                    <jats:sup>+<\/jats:sup>\n                    cytotoxic T cells, and CD69\n                    <jats:sup>+<\/jats:sup>\n                    IFN-\u03b3\n                    <jats:sup>+<\/jats:sup>\n                    TNF\u03b1\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    \/CD8\n                    <jats:sup>+<\/jats:sup>\n                    effector T cells; (\n                    <jats:italic>ii<\/jats:italic>\n                    ) reduced morbidity, viral load, lung pathology, and COVID-19-like symptoms from various VOCs, including the pathogenic B.1.617.2 Delta and the recent KP.3 Omicron variants; (\n                    <jats:italic>iii<\/jats:italic>\n                    ) improved protection conferred by spike-alone mRNA; and (\n                    <jats:italic>iv<\/jats:italic>\n                    ) conferred protection that lasted for more than 1 year. This multi-antigen CoV vaccine could provide potent, broad-spectrum, and durable cross-protective immunity against current and future variants of concern in the clinic.\n                  <\/jats:p>","DOI":"10.1038\/s41541-026-01549-y","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:34:36Z","timestamp":1787056476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants"],"prefix":"10.1038","volume":"11","author":[{"given":"Swayam","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha R.","family":"Dhanushkodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshana","family":"Quadiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Vahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz A.","family":"Chentoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Gregoire","family":"Coulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela Coimbra","family":"Ibraim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assia","family":"El Babsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia F.","family":"Tifrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar J.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lbachir","family":"BenMohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"1549_CR1","first-page":"45","volume":"29","author":"S Prakash","year":"2024","unstructured":"Prakash, S. et al. Cross-protection induced by highly conserved human B, CD4 (+,) and CD8 (+) T cell epitopes-based coronavirus vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front. Immunol. 29, 45\u201356 (2024).","journal-title":"Front. Immunol."},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.2300392","volume":"212","author":"NR Dhanushkodi","year":"2024","unstructured":"Dhanushkodi, N. R. et al. Anti-viral and anti-inflammatory therapeutic effect of RAGE-Ig protein against multiple SARS-CoV-2 variants of concern demonstrated in K18-hACE2 mouse and Syrian golden hamster models. J. Immunol. 212, 1\u201310 (2024).","journal-title":"J. Immunol."},{"key":"1549_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.01096-23","volume":"97","author":"L Zayou","year":"2023","unstructured":"Zayou, L. et al. A multi-epitope\/CXCL11 prime\/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4(+) and CD8(+) T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection. J. Virol. 97, 1\u201313 (2023).","journal-title":"J. Virol."},{"key":"1549_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.4049\/jimmunol.2300315","volume":"211","author":"JP Evans","year":"2023","unstructured":"Evans, J. P. & Liu, S. L. Challenges and prospects in developing future SARS-CoV-2 vaccines: overcoming original antigenic sin and inducing broadly neutralizing antibodies. J. Immunol. 211, 1459\u20131467 (2023).","journal-title":"J. Immunol."},{"key":"1549_CR5","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.4049\/jimmunol.2001438","volume":"206","author":"S Prakash","year":"2021","unstructured":"Prakash, S. et al. Genome-wide B cell, CD4(+), and CD8(+) T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines. J. Immunol. 206, 2566\u20132582 (2021).","journal-title":"J. Immunol."},{"key":"1549_CR6","doi-asserted-by":"crossref","unstructured":"Pedersen, S. F. & Ho, Y. C. SARS-CoV-2: a storm is raging. J. Clin. Investig. 130, 2202\u20132205 (2020).","DOI":"10.1172\/JCI137647"},{"key":"1549_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34439-7","volume":"13","author":"S Sharma","year":"2022","unstructured":"Sharma, S. et al. Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. Nat. Commun. 13, 6644 (2022).","journal-title":"Nat. Commun."},{"key":"1549_CR8","doi-asserted-by":"crossref","unstructured":"Sunagar, R., Singh, A. & Kumar, S. SARS-CoV-2: immunity, challenges with current vaccines, and a novel perspective on mucosal vaccines. Vaccines 11, 849 (2023).","DOI":"10.3390\/vaccines11040849"},{"key":"1549_CR9","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.cell.2021.03.052","volume":"184","author":"NL Washington","year":"2021","unstructured":"Washington, N. L. et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. Cell 184, 2587\u20132594 e2587 (2021).","journal-title":"Cell"},{"key":"1549_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41564-021-00932-w","volume":"6","author":"F Konings","year":"2021","unstructured":"Konings, F. et al. SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nat. Microbiol. 6, 821\u2013823 (2021).","journal-title":"Nat. Microbiol."},{"key":"1549_CR11","doi-asserted-by":"crossref","unstructured":"Bellocchi, M. C. et al. Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in Central Italy: a refined analysis by next generation sequencing. Viruses 15, 1711 (2023).","DOI":"10.3390\/v15081711"},{"key":"1549_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58766-7","volume":"16","author":"S Beale","year":"2025","unstructured":"Beale, S. et al. Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort. Nat. Commun. 16, 3686 (2025).","journal-title":"Nat. Commun."},{"key":"1549_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41591-024-03173-6","volume":"30","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly, Z. et al. Long COVID science, research and policy. Nat. Med. 30, 2148\u20132164 (2024).","journal-title":"Nat. Med."},{"key":"1549_CR15","doi-asserted-by":"publisher","first-page":"ofaf533","DOI":"10.1093\/ofid\/ofaf533","volume":"12","author":"Y Hou","year":"2025","unstructured":"Hou, Y. et al. Global Prevalence of Long COVID, Its Subtypes, and Risk Factors: An Updated Systematic Review and Meta-analysis. Open Forum Infect Dis. 12, ofaf533 (2025).","journal-title":"Open Forum Infect Dis."},{"key":"1549_CR16","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1016\/j.cell.2021.09.010","volume":"184","author":"M Cevik","year":"2021","unstructured":"Cevik, M., Grubaugh, N. D., Iwasaki, A. & Openshaw, P. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 5077\u20135081 (2021).","journal-title":"Cell"},{"key":"1549_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"1549_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1182556","volume":"14","author":"TM Renner","year":"2023","unstructured":"Renner, T. M. et al. Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern. Front. Immunol. 14, 1182556 (2023).","journal-title":"Front. Immunol."},{"key":"1549_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195299","volume":"14","author":"Q Ma","year":"2023","unstructured":"Ma, Q. et al. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern. Front. Immunol. 14, 1195299 (2023).","journal-title":"Front. Immunol."},{"key":"1549_CR20","first-page":"e60","volume":"387","author":"EJ Rubin","year":"2022","unstructured":"Rubin, E. J., Baden, L. R., Marks, P. & Morrissey, S. Audio interview: the FDA and Covid-19 vaccines. N. Engl. J. Med. 387, e60 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1549_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(20)30743-1","volume":"395","author":"G Chowell","year":"2020","unstructured":"Chowell, G. & Mizumoto, K. The COVID-19 pandemic in the USA: What might we expect?. Lancet 395, 1093\u20131094 (2020).","journal-title":"Lancet"},{"key":"1549_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0140-6736(23)00050-8","volume":"401","author":"L The","year":"2023","unstructured":"The, L. The COVID-19 pandemic in 2023: far from over. Lancet 401, 79 (2023).","journal-title":"Lancet"},{"key":"1549_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/14760584.2022.2110075","volume":"21","author":"T Park","year":"2022","unstructured":"Park, T. et al. Vaccines against SARS-CoV-2 variants and future pandemics. Expert Rev. Vaccines 21, 1363\u20131376 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"1549_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"1549_CR26","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142167","volume":"5","author":"D Schub","year":"2020","unstructured":"Schub, D. et al. High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. JCI insight 5, e142167 (2020).","journal-title":"JCI insight"},{"key":"1549_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861\u2013880 (2021).","journal-title":"Cell"},{"key":"1549_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012 e1019 (2020).","journal-title":"Cell"},{"key":"1549_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688436","volume":"12","author":"I Brand","year":"2021","unstructured":"Brand, I. et al. Broad T cell targeting of structural proteins after SARS-CoV-2 infection: high throughput assessment of T cell reactivity using an automated interferon gamma release assay. Front. Immunol. 12, 688436 (2021).","journal-title":"Front. Immunol."},{"key":"1549_CR30","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange, E. M. et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 27, 1280\u20131289 (2021).","journal-title":"Nat. Med."},{"key":"1549_CR31","doi-asserted-by":"crossref","unstructured":"Shi, J. et al. A T cell-based SARS-CoV-2 spike protein vaccine provides protection without antibodies. JCI Insight 9, e155789 (2024).","DOI":"10.1172\/jci.insight.155789"},{"key":"1549_CR32","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","volume":"44","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379\u20131391 (2016).","journal-title":"Immunity"},{"key":"1549_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","volume":"601","author":"L Swadling","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"1549_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41590-022-01292-1","volume":"23","author":"MO Diniz","year":"2022","unstructured":"Diniz, M. O. et al. Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2. Nat. Immunol. 23, 1324\u20131329 (2022).","journal-title":"Nat. Immunol."},{"key":"1549_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27674-x","volume":"13","author":"R Kundu","year":"2022","unstructured":"Kundu, R. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat. Commun. 13, 80 (2022).","journal-title":"Nat. Commun."},{"key":"1549_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42433-w","volume":"14","author":"E Mitsi","year":"2023","unstructured":"Mitsi, E. et al. Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination. Nat. Commun. 14, 6815 (2023).","journal-title":"Nat. Commun."},{"key":"1549_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19770-1","volume":"11","author":"L Yan","year":"2020","unstructured":"Yan, L. et al. Architecture of a SARS-CoV-2 mini replication and transcription complex. Nat. Commun. 11, 5874 (2020).","journal-title":"Nat. Commun."},{"key":"1549_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-020-2739-1","volume":"589","author":"Y Finkel","year":"2021","unstructured":"Finkel, Y. et al. The coding capacity of SARS-CoV-2. Nature 589, 125\u2013130 (2021).","journal-title":"Nature"},{"key":"1549_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89\u201394 (2020).","journal-title":"Science"},{"key":"1549_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188605","volume":"14","author":"C Primard","year":"2023","unstructured":"Primard, C. et al. OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Front. Immunol. 14, 1188605 (2023).","journal-title":"Front. Immunol."},{"key":"1549_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343716","volume":"15","author":"PG Coulon","year":"2024","unstructured":"Coulon, P. G. et al. High frequencies of alpha common cold coronavirus\/SARS-CoV-2 cross-reactive functional CD4(+) and CD8(+) memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients. Front. Immunol. 15, 1343716 (2024).","journal-title":"Front. Immunol."},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","volume":"969","author":"N Pardi","year":"2013","unstructured":"Pardi, N., Muramatsu, H., Weissman, D. & Kariko, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969, 29\u201342 (2013).","journal-title":"Methods Mol. Biol."},{"key":"1549_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201616119","volume":"119","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc. Natl. Acad. Sci. USA 119, e2201616119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110105119","volume":"119","author":"M Lu","year":"2022","unstructured":"Lu, M. et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proc. Natl. Acad. Sci. USA 119, e2110105119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR45","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"1549_CR46","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"1549_CR47","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR48","doi-asserted-by":"crossref","unstructured":"Dowall, S. et al. Development of a hamster natural transmission model of SARS-CoV-2 infection. Viruses 13, 2251 (2021).","DOI":"10.3390\/v13112251"},{"key":"1549_CR49","doi-asserted-by":"crossref","unstructured":"Monchatre-Leroy, E. et al. Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2. J. Gen. Virol. 102, 001567 (2021).","DOI":"10.1099\/jgv.0.001567"},{"key":"1549_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41592-022-01447-w","volume":"19","author":"H Chu","year":"2022","unstructured":"Chu, H., Chan, J. F. & Yuen, K. Y. Animal models in SARS-CoV-2 research. Nat. Methods 19, 392\u2013394 (2022).","journal-title":"Nat. Methods"},{"key":"1549_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq1945","volume":"14","author":"RL Hajnik","year":"2022","unstructured":"Hajnik, R. L. et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci. Transl. Med. 14, eabq1945 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1549_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863554","volume":"13","author":"S Desmecht","year":"2022","unstructured":"Desmecht, S. et al. Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects: impact of booster dose and breakthrough infections. Front. Immunol. 13, 863554 (2022).","journal-title":"Front. Immunol."},{"key":"1549_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29413-2","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu, H. et al. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat. Commun. 13, 1891 (2022).","journal-title":"Nat. Commun."},{"key":"1549_CR54","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jmv.27526","volume":"94","author":"S Kumar","year":"2022","unstructured":"Kumar, S., Thambiraja, T. S., Karuppanan, K. & Subramaniam, G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J. Med. Virol. 94, 1641\u20131649 (2022).","journal-title":"J. Med. Virol."},{"key":"1549_CR55","doi-asserted-by":"crossref","unstructured":"Chakraborty, D. et al. Stabilizing prefusion SARS-CoV-2 spike by destabilizing the postfusion conformation. Vaccines 13, 315 (2025).","DOI":"10.3390\/vaccines13030315"},{"key":"1549_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56293-x","volume":"14","author":"L Rutten","year":"2024","unstructured":"Rutten, L. et al. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity. Sci. Rep. 14, 5735 (2024).","journal-title":"Sci. Rep."},{"key":"1549_CR57","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","volume":"52","author":"N Vabret","year":"2020","unstructured":"Vabret, N. et al. Immunology of COVID-19: current state of the science. Immunity 52, 910\u2013941 (2020).","journal-title":"Immunity"},{"key":"1549_CR58","doi-asserted-by":"crossref","unstructured":"Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020).","DOI":"10.7554\/eLife.61312"},{"key":"1549_CR59","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"1549_CR60","doi-asserted-by":"publisher","first-page":"e1009761","DOI":"10.1371\/journal.ppat.1009761","volume":"17","author":"S Boppana","year":"2021","unstructured":"Boppana, S. et al. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog. 17, e1009761 (2021).","journal-title":"PLoS Pathog."},{"key":"1549_CR61","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.4049\/jimmunol.2101142","volume":"208","author":"Y Yuzefpolskiy","year":"2022","unstructured":"Yuzefpolskiy, Y. et al. Cutting edge: effect of disease-modifying therapies on SARS-CoV-2 vaccine-induced immune responses in multiple sclerosis patients. J. Immunol. 208, 1519\u20131524 (2022).","journal-title":"J. Immunol."},{"key":"1549_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38020-8","volume":"14","author":"TM Eser","year":"2023","unstructured":"Eser, T. M. et al. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion. Nat. Commun. 14, 2952 (2023).","journal-title":"Nat. Commun."},{"key":"1549_CR63","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 8, 420\u2013422 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1549_CR64","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1549_CR65","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","volume":"15","author":"S Tian","year":"2020","unstructured":"Tian, S. et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol. 15, 700\u2013704 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"1549_CR66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/his.14134","volume":"77","author":"T Menter","year":"2020","unstructured":"Menter, T. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77, 198\u2013209 (2020).","journal-title":"Histopathology"},{"key":"1549_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"W Hong","year":"2021","unstructured":"Hong, W. et al. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduct. Target. Ther. 6, 1 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1549_CR68","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"1549_CR69","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085.e12 (2020).","journal-title":"Cell"},{"key":"1549_CR70","doi-asserted-by":"crossref","unstructured":"Amruta, N. et al. Mouse adapted SARS-CoV-2 (MA10) viral infection induces neuroinflammation in standard laboratory mice. Viruses 15, 114 (2022).","DOI":"10.3390\/v15010114"},{"key":"1549_CR71","doi-asserted-by":"crossref","unstructured":"Allnoch, L. et al. Vascular inflammation is associated with loss of aquaporin 1 expression on endothelial cells and increased fluid leakage in SARS-CoV-2 infected golden Syrian hamsters. Viruses 13, 639 (2021).","DOI":"10.3390\/v13040639"},{"key":"1549_CR72","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1549_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19684-y","volume":"11","author":"R Boudewijns","year":"2020","unstructured":"Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).","journal-title":"Nat. Commun."},{"key":"1549_CR74","doi-asserted-by":"publisher","first-page":"106239","DOI":"10.1016\/j.rmed.2020.106239","volume":"176","author":"SS Batah","year":"2021","unstructured":"Batah, S. S. & Fabro, A. T. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. Respir. Med. 176, 106239 (2021).","journal-title":"Respir. Med."},{"key":"1549_CR75","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41379-020-0595-z","volume":"33","author":"IM Schaefer","year":"2020","unstructured":"Schaefer, I. M. et al. In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. Mod. Pathol. 33, 2104\u20132114 (2020).","journal-title":"Mod. Pathol."},{"key":"1549_CR76","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1038\/s41379-020-00661-1","volume":"33","author":"AC Borczuk","year":"2020","unstructured":"Borczuk, A. C. et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Mod. Pathol. 33, 2156\u20132168 (2020).","journal-title":"Mod. Pathol."},{"key":"1549_CR77","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings, M. J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395, 1763\u20131770 (2020).","journal-title":"Lancet"},{"key":"1549_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110829","volume":"39","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 39, 110829 (2022).","journal-title":"Cell Rep."},{"key":"1549_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45274-3","volume":"15","author":"T Tamura","year":"2024","unstructured":"Tamura, T. et al. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. Nat. Commun. 15, 1176 (2024).","journal-title":"Nat. Commun."},{"key":"1549_CR80","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"1549_CR81","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1073\/pnas.1201130109","volume":"109","author":"M Bouvet","year":"2012","unstructured":"Bouvet, M. et al. RNA 3\u2019-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10\/nsp14 exoribonuclease complex. Proc. Natl. Acad. Sci. USA 109, 9372\u20139377 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR82","doi-asserted-by":"crossref","unstructured":"Hsu, J. C., Laurent-Rolle, M., Pawlak, J. B., Wilen, C. B. & Cresswell, P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc. Natl. Acad. Sci. USA 118, e2101161118 (2021).","DOI":"10.1073\/pnas.2101161118"},{"key":"1549_CR83","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1073\/pnas.1718806115","volume":"115","author":"F Ferron","year":"2018","unstructured":"Ferron, F. et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl. Acad. Sci. USA 115, E162\u2013E171 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR84","unstructured":"Le Bert, N. et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 218, e20202617 (2021)."},{"key":"1549_CR85","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1073\/pnas.0808790106","volume":"106","author":"Y Chen","year":"2009","unstructured":"Chen, Y. et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc. Natl. Acad. Sci. USA 106, 3484\u20133489 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117142119","volume":"119","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y. et al. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Proc. Natl. Acad. Sci. USA 119, e2117142119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1549_CR87","doi-asserted-by":"publisher","first-page":"e1000054","DOI":"10.1371\/journal.ppat.1000054","volume":"4","author":"MJ van Hemert","year":"2008","unstructured":"van Hemert, M. J. et al. SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog. 4, e1000054 (2008).","journal-title":"PLoS Pathog."},{"key":"1549_CR88","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-4939-2438-7_22","volume":"1282","author":"MC Hagemeijer","year":"2015","unstructured":"Hagemeijer, M. C. & de Haan, C. A. Studying the dynamics of coronavirus replicative structures. Methods Mol. Biol. 1282, 261\u2013269 (2015).","journal-title":"Methods Mol. Biol."},{"key":"1549_CR89","doi-asserted-by":"publisher","first-page":"e1011032","DOI":"10.1371\/journal.ppat.1011032","volume":"19","author":"A Becerra-Artiles","year":"2023","unstructured":"Becerra-Artiles, A. et al. Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2. PLoS Pathog. 19, e1011032 (2023).","journal-title":"PLoS Pathog."},{"key":"1549_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012171","volume":"20","author":"CE Snedden","year":"2024","unstructured":"Snedden, C. E. & Lloyd-Smith, J. O. Predicting the presence of infectious virus from PCR data: A meta-analysis of SARS-CoV-2 in non-human primates. PLoS Pathog. 20, e1012171 (2024).","journal-title":"PLoS Pathog."},{"key":"1549_CR91","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13578-021-00643-z","volume":"11","author":"AC Brant","year":"2021","unstructured":"Brant, A. C., Tian, W., Majerciak, V., Yang, W. & Zheng, Z. M. SARS-CoV-2: from its discovery to genome structure, transcription, and replication. Cell Biosci. 11, 136 (2021).","journal-title":"Cell Biosci."},{"key":"1549_CR92","doi-asserted-by":"publisher","first-page":"e0107125","DOI":"10.1128\/mbio.01071-25","volume":"16","author":"N Thakur","year":"2025","unstructured":"Thakur, N., Chakraborty, P., Tufariello, J. M. & Basler, C. F. SARS-CoV-2 Nsp14 binds Tollip and activates pro-inflammatory pathways while downregulating interferon-alpha and interferon-gamma receptors. mBio 16, e0107125 (2025).","journal-title":"mBio"},{"key":"1549_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974364","volume":"13","author":"A Ghaemi","year":"2022","unstructured":"Ghaemi, A. et al. Recombinant COVID-19 vaccine based on recombinant RBD\/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity. Front. Immunol. 13, 974364 (2022).","journal-title":"Front. Immunol."},{"key":"1549_CR94","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202215821","volume":"14","author":"S Appelberg","year":"2022","unstructured":"Appelberg, S. et al. A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells. EMBO Mol. Med. 14, e15821 (2022).","journal-title":"EMBO Mol. Med."},{"key":"1549_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.910136","volume":"13","author":"A Rice","year":"2022","unstructured":"Rice, A. et al. Heterologous saRNA prime, DNA dual-antigen boost SARS-CoV-2 vaccination elicits robust cellular immunogenicity and cross-variant neutralizing antibodies. Front. Immunol. 13, 910136 (2022).","journal-title":"Front. Immunol."},{"key":"1549_CR96","first-page":"177","volume":"5","author":"MS Khan","year":"2022","unstructured":"Khan, M. S. et al. Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. Antib. Ther. 5, 177\u2013191 (2022).","journal-title":"Antib. Ther."},{"key":"1549_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2022.105082","volume":"25","author":"M Hasanpourghadi","year":"2023","unstructured":"Hasanpourghadi, M. et al. Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. Microbes Infect. 25, 105082 (2023).","journal-title":"Microbes Infect."},{"key":"1549_CR98","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","volume":"3","author":"F Chiuppesi","year":"2022","unstructured":"Chiuppesi, F. et al. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe 3, e252\u2013e264 (2022).","journal-title":"Lancet Microbe"},{"key":"1549_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1503954","volume":"16","author":"L Zayou","year":"2025","unstructured":"Zayou, L. et al. Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19. Front. Immunol. 16, 1503954 (2025).","journal-title":"Front. Immunol."},{"key":"1549_CR100","doi-asserted-by":"publisher","unstructured":"Prakash, S. et al. A broad-spectrum multi-antigen mRNA\/LNP-based pan-coronavirus vaccine induced potent cross-protective immunity against infection and disease caused by highly pathogenic and heavily spike-mutated SARS-CoV-2 variants of concern in the Syrian hamster model. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.02.14.580225 (2024).","DOI":"10.1101\/2024.02.14.580225"},{"key":"1549_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31005-z","volume":"13","author":"AR Rappaport","year":"2022","unstructured":"Rappaport, A. R. et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat. Commun. 13, 3289 (2022).","journal-title":"Nat. Commun."},{"key":"1549_CR102","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","volume":"186","author":"CM Arieta","year":"2023","unstructured":"Arieta, C. M. et al. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell 186, 2392\u20132409.e21 (2023).","journal-title":"Cell"},{"key":"1549_CR103","doi-asserted-by":"crossref","unstructured":"Dervillez, X. et al. \u201cAsymptomatic\u201d HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J. Immunol. 191, 5124\u20135138 (2013).","DOI":"10.4049\/jimmunol.1301415"},{"key":"1549_CR104","doi-asserted-by":"crossref","unstructured":"Boucherma, R. et al. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 monochain transgenic\/H-2 class I null mice: novel versatile preclinical models of human T cell responses. J. Immunol. 191, 583\u2013593 (2013).","DOI":"10.4049\/jimmunol.1300483"},{"key":"1549_CR105","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002510050594","volume":"50","author":"A Sette","year":"1999","unstructured":"Sette, A. & Sidney, J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50, 201\u2013212 (1999).","journal-title":"Immunogenetics"},{"key":"1549_CR106","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0952-7915(98)80124-6","volume":"10","author":"A Sette","year":"1998","unstructured":"Sette, A. & Sidney, J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10, 478\u2013482 (1998).","journal-title":"Curr. Opin. Immunol."},{"key":"1549_CR107","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1093\/Bioinformatics\/btl324","volume":"23","author":"T Hertz","year":"2007","unstructured":"Hertz, T. & Yanover, C. Identifying HLA supertypes by learning distance functions. Bioinformatics 23, e148\u2013e155 (2007).","journal-title":"Bioinformatics"},{"key":"1549_CR108","doi-asserted-by":"crossref","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","DOI":"10.1038\/s41586-020-2312-y"},{"key":"1549_CR109","doi-asserted-by":"crossref","unstructured":"Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents 55, 105954 (2020).","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"1549_CR110","doi-asserted-by":"crossref","unstructured":"Vaninov, N. In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol. 20, 277 (2020).","DOI":"10.1038\/s41577-020-0305-6"},{"key":"1549_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108408","volume":"214","author":"J Ma","year":"2020","unstructured":"Ma, J. et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin. Immunol. 214, 108408 (2020).","journal-title":"Clin. Immunol."},{"key":"1549_CR112","doi-asserted-by":"crossref","unstructured":"Henderson, L. A. et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 72, 1059\u20131063 (2020).","DOI":"10.1002\/art.41285"},{"key":"1549_CR113","doi-asserted-by":"crossref","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 12, eabb5883 (2020).","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"1549_CR114","doi-asserted-by":"crossref","unstructured":"Li, K. et al. Single-dose, intranasal immunization with recombinant parainfluenza virus 5 expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) spike protein protects mice from fatal MERS-CoV infection. mBio 11, e00554-20 (2020).","DOI":"10.1128\/mBio.00554-20"},{"key":"1549_CR115","doi-asserted-by":"crossref","unstructured":"Kim, E. et al. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine 55, 102743 (2020).","DOI":"10.1016\/j.ebiom.2020.102743"},{"key":"1549_CR116","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr.","year":"2007","unstructured":"McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"1549_CR117","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41577-022-00809-x","volume":"23","author":"SM Murray","year":"2023","unstructured":"Murray, S. M. et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat. Rev. Immunol. 23, 304\u2013316 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1549_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106685","volume":"26","author":"R Morita","year":"2023","unstructured":"Morita, R. et al. COVID-19 relapse associated with SARS-CoV-2 evasion from CD4(+) T-cell recognition in an agammaglobulinemia patient. iScience 26, 106685 (2023).","journal-title":"iScience"},{"key":"1549_CR119","doi-asserted-by":"crossref","unstructured":"Sabatino, J. J., Jr et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight 7, e156978 (2022).","DOI":"10.1172\/jci.insight.156978"},{"key":"1549_CR120","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv4214","volume":"17","author":"H Park","year":"2025","unstructured":"Park, H. et al. Longitudinal antibody titers measured after COVID-19 mRNA vaccination can identify individuals at risk for subsequent infection. Sci. Transl. Med. 17, eadv4214 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1549_CR121","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Munoz-Fontela","year":"2020","unstructured":"Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"1549_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328905","volume":"15","author":"S Prakash","year":"2024","unstructured":"Prakash, S. et al. Cross-protection induced by highly conserved human B, CD4(+), and CD8(+) T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front. Immunol. 15, 1328905 (2024).","journal-title":"Front. Immunol."},{"key":"1549_CR123","doi-asserted-by":"crossref","unstructured":"Ma, Y., VanKeulen-Miller, R. & Fenton, O. S. mRNA lipid nanoparticle formulation, characterization and evaluation. Nat. Protoc. 20, 2618\u20132651 (2025).","DOI":"10.1038\/s41596-024-01134-4"},{"key":"1549_CR124","doi-asserted-by":"crossref","unstructured":"Quadiri, A. et al. A spike-based mRNA vaccine encapsulated in phospholipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine containing lipid nanoparticles induced potent B- and T-cell responses associated with protection against SARS-CoV-2 infection and COVID-19-like symptoms in hamsters. Vaccines 13, 47 (2025).","DOI":"10.3390\/vaccines13010047"},{"key":"1549_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."},{"key":"1549_CR126","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","volume":"44","author":"G Matute-Bello","year":"2011","unstructured":"Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol. 44, 725\u2013738 (2011).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1549_CR127","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/mco2.98","volume":"2","author":"Z Bi","year":"2021","unstructured":"Bi, Z., Hong, W., Yang, J., Lu, S. & Peng, X. Animal models for SARS-CoV-2 infection and pathology. MedComm 2, 548\u2013568 (2021).","journal-title":"MedComm"},{"key":"1549_CR128","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/s41590-020-0794-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. Publisher Correction: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1470 (2020).","journal-title":"Nat. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01549-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01549-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:03:33Z","timestamp":1791245013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01549-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01549-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.B.M. has an equity interest in TechImmune, LLC., a company that may potentially benefit from the research results and serves on the company\u2019s Scientific Advisory Board. L.B.M.\u2019s relationship with TechImmune, LLC., has been reviewed and approved by the University of California, Irvine under its conflict-of-interest policies.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"185"}}